BLOG

What Does Autologous Mean in Stem Cell Therapy? A Guide for Patients in Osaka

Published 2026.10.21 7 min read

Hello, I am Dr. Hidenori Shimada of Grand Green Osaka Umekita Clinic in Osaka, Japan.

When people research regenerative medicine abroad, one question comes up quickly: whose cells are actually being used? In adipose-derived stem cell therapy, the answer matters for how the treatment is planned, how it is regulated, and which questions are worth asking at a consultation. This guide explains what autologous cells are, what that term does and does not imply, and how international patients can prepare before speaking with a physician at Grand Green Osaka Umekita Clinic in Osaka.

In short: using your own cells may lower the likelihood of rejection or allergic reaction compared with donor cells or artificial materials, but it does not remove all risk and it does not promise any particular result. Whether the treatment is appropriate for you is a decision for a doctor after an examination.

What does autologous mean in stem cell therapy?

Autologous simply means that the cells come from the same person who later receives them. In the adipose-derived approach described by Grand Green Osaka Umekita Clinic, a very small amount of fat tissue is collected, mesenchymal stem cells are isolated and expanded in culture at a specialized facility, and the cultured cells are then returned to the same patient by intravenous infusion.

This contrasts with allogeneic therapy, in which cells come from a donor, and with products made from synthetic or animal-derived materials. Because autologous cells are your own, the immune system is less likely to treat them as foreign. The clinic describes this as a lower risk of rejection or allergic reaction than donor cells or artificial materials. Lower is not the same as none, and the medical literature on mesenchymal stem cells continues to evolve, so it is reasonable to ask your doctor how this applies to your own situation.

Why fat tissue is used as the cell source

Mesenchymal stem cells can be found in several tissues, including bone marrow and fat. Bone marrow collection places a considerable burden on the body. Fat tissue is generally considered to contain a larger number of mesenchymal stem cells than bone marrow, and it can be collected through a small incision under local anesthesia. According to the clinic, only a few rice-grain-sized pieces of fat are needed.

For an international patient, this has a practical side: collection and infusion are carried out on an outpatient basis, without hospitalization. That can make it easier to think through a trip to Osaka. Even so, the exact schedule, the time needed for culture, and any follow-up should be confirmed directly with the clinic rather than assumed from general descriptions online.

What autologous cells cannot tell you

It is easy to read the phrase “your own cells” as a signal that a treatment is gentle or free of concerns. That reading goes further than the evidence supports. Several points are worth keeping in mind.

Autologous does not mean risk-free. Fat collection, cell culture, and infusion each carry their own potential complications, which a physician should explain.
Your own cells can still change during culture, so quality control and processing standards at the culture facility are important topics to ask about.
Research on mesenchymal stem cells, including reports of anti-inflammatory signaling and the homing effect, is promising in some areas but does not establish a guaranteed outcome for any individual.
The treatment is not a replacement for standard medical care for any condition, and it should be discussed alongside your current treatments.

Reading studies on PubMed can help you form questions, but results from one study or one patient group should not be generalized to everyone. A good consultation will separate what has been reported in research from what can reasonably be expected in your specific case.

How the treatment is provided under Japanese law

In Japan, regenerative medicine using cultured cells is provided under the Act on the Safety of Regenerative Medicine. Clinics that offer this type of therapy submit a provision plan, and cell processing is carried out at a facility that meets regulatory requirements. Grand Green Osaka Umekita Clinic describes its treatment as managed under this framework.

It is also important to understand that adipose-derived stem cell therapy is a self-pay treatment, meaning it is not covered by Japan’s public health insurance. Fees, the number of infusions, possible risks and side effects, and whether you are a suitable candidate all need to be confirmed with a doctor at the clinic. Please check the fee and FAQ sections of the treatment page and ask for a written explanation if you need one for your home physician.

Questions to prepare before your consultation in Osaka

A little preparation can make a first conversation more productive, especially when you are communicating across languages and time zones. The following questions are a reasonable starting point.

Will my own cells be collected, cultured, and returned only to me, and how is the process documented?
What are the possible risks and side effects of fat collection and intravenous infusion for someone with my medical history?
How is the treatment positioned relative to the standard care I already receive at home?
What are the total costs, and what is and is not included, given that the treatment is not covered by insurance?
What follow-up is recommended after I return home, and can records be shared with my home doctor?

Grand Green Osaka Umekita Clinic, located in the Umeda area of Osaka, provides an information page for international patients and can be contacted through its web or LINE channels. Reviewing the treatment page first, and then arranging a consultation, lets a physician examine you and explain whether this approach fits your circumstances. Bringing your recent medical records and a list of your current medications is also helpful.

Understanding what autologous means, and what it does not mean, is a sensible first step. The decision itself should always rest on a careful discussion with a qualified doctor.

Autologous Cells: Key Points

Your own cellsCollected from your fat tissue
Not risk-freeAsk about possible risks
Japanese regulationProvision plan required
Doctor consultationSuitability is decided by a doctor

This figure is a conceptual diagram summarizing the article

Learn more about Adipose-Derived Stem Cell Therapy

References

Supervising Physician

Director, Medical Corporation Shimada Clinic
Head of Clinical Practice, Grand Green Osaka Umekita Clinic

Hidenori Shimada

Graduated from the University of Tokushima Faculty of Medicine in 2005. After his initial residency, he obtained U.S. medical certification (ECFMG) and trained as a sub-intern in general surgery at the University of Washington. After completing the doctoral program at Kyoto University Graduate School of Medicine and working as a researcher at the Center for iPS Cell Research and Application (CiRA), Kyoto University, he founded Shimada Clinic in 2013. At Grand Green Osaka Umekita Clinic (https://umekitaclinic.org), he is engaged in a wide range of care, from internal medicine and pediatrics to cell therapy and aesthetic medicine.

* The physician supervision of this article covers its academic content only and does not constitute a recommendation of any specific treatment or product.

Back to article list › Back to Adipose-Derived Stem Cell Therapy ›